The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for patients, experts say.

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

Halozyme announces US FDA approval of argenx's Vyvgart Hytrulo prefilled syringe co-formulated with ENHANZE for self-injection for gMG and CIDP: San Diego Monday, April 14, 2025, ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

The U.S. Food and Drug Administration (FDA) has approved Dutch biotech argenx’s (NASDAQ:ARGX) (OTCPK:ARGNF) autoimmune ...

The safety needle that is 25G, 5/8 inches length, and thin wall type is not included in the carton. After proper training on subcutaneous injection technique, the prefilled syringe may be ...